Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma

被引：0
|
作者：
Jang Ho Cho
Hyun Ae Jung
Se-Hoon Lee
Jin Seok Ahn
Myung-Ju Ahn
Keunchil Park
Jong-Mu Sun
机构：
[1] Sungkyunkwan University School of Medicine,Division of Hematology
来源：
Journal of Cancer Research and Clinical Oncology | 2019年 / 145卷
关键词：
Pulmonary adenocarcinoma; Epidermal growth factor receptor; Programmed cell death-ligand 1; Predictive factor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1341 / 1349
页数：8
相关论文
共 50 条
  • [31] Real-world efficacy of PD-1/PD-L1 inhibitors in patients with advanced pulmonary neuroendocrine carcinoma: a single-center analysis
    Zhai, Wanchen
    Yu, Ying
    Wu, Haicheng
    Zhang, Qian
    Chen, Yunfei
    Yang, Yehao
    Fan, Yun
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [32] Clinical impact of tumour burden on the efficacy of PD-1/PD-L1 inhibitors plus chemotherapy in non-small-cell lung cancer
    Miyawaki, Taichi
    Kenmotsu, Hirotsugu
    Doshita, Kosei
    Kodama, Hiroaki
    Nishioka, Naoya
    Iida, Yuko
    Miyawaki, Eriko
    Mamesaya, Nobuaki
    Kobayashi, Haruki
    Omori, Shota
    Ko, Ryo
    Wakuda, Kazushige
    Ono, Akira
    Naito, Tateaki
    Murakami, Haruyasu
    Mori, Keita
    Harada, Hideyuki
    Endo, Masahiro
    Takahashi, Kazuhisa
    Takahashi, Toshiaki
    CANCER MEDICINE, 2023, 12 (02): : 1451 - 1460
  • [33] Development and validation of a nomogram to predicting the efficacy of PD-1/PD-L1 inhibitors in patients with nasopharyngeal carcinoma
    Chen, Yao
    Chen, Dubo
    Wang, Ruizhi
    Xie, Shuhua
    Wang, Xueping
    Huang, Hao
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (10): : 2601 - 2607
  • [34] Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors
    Abdin, Shifaa M.
    Zaher, Dana M.
    Arafa, El-Shaimaa A.
    Omar, Hany A.
    CANCERS, 2018, 10 (02)
  • [35] Beyond chemotherapy for advanced disease-the role of EGFR and PD-1 inhibitors
    Gu, Weijie
    Zhu, Yao
    Ye, Dingwei
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2017, 6 (05) : 848 - 854
  • [36] Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis
    Chen, Shixue
    Zhang, Zhibo
    Zheng, Xuan
    Tao, Haitao
    Zhang, Sujie
    Ma, Junxun
    Liu, Zhefeng
    Wang, Jinliang
    Qian, Yuanyu
    Cui, Pengfei
    Huang, Di
    Huang, Ziwei
    Wu, Zhaozhen
    Hu, Yi
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [37] CORRELATION BETWEEN PERIPHERAL BLOOD BIOMARKERS AND CLINICAL EFFICACY OF PD-1/PD-L1 INHIBITORS IN THE TREATMENT OF CHOLANGIOCARCINOMA
    Zeng, Fanli
    Wang, Donghe
    Yang, Heqing
    ACTA MEDICA MEDITERRANEA, 2022, 38 (05): : 2979 - 2984
  • [38] Rheumatologic symptoms in oncologic patients on PD-1 inhibitors
    Kuswanto, Wilson F.
    MacFarlane, Lindsey A.
    Gedmintas, Lydia
    Mulloy, Alexandra
    Choueiri, Toni K.
    Bermas, Bonnie L.
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2018, 47 (06) : 907 - 910
  • [39] Impact of Timing the Combination of Radiotherapy and PD-1 Inhibitors on Outcomes in Patients with Hepatocellular Carcinoma
    Zhong, Liting
    Peng, Weiwei
    Sun, Jingyuan
    Luo, Yongyi
    Sheng, Hailong
    Wu, Yi
    Zhou, Tonggang
    Zhou, Chaoming
    Cao, Chuanhui
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2025, 12 : 123 - 134
  • [40] Efficacy and safety of adjuvant therapy with PD-1/PD-L1 inhibitors in cancer
    Mo, Dun-Chang
    Liang, Zi-Yu
    Chen, Long
    Huang, Jian-Feng
    Luo, Peng-Hui
    Wang, Han-Lei
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2022, 24 (06)
12345